Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KIN

Kindred Biosciences (KIN) Stock Price, News & Analysis

Kindred Biosciences logo

About Kindred Biosciences Stock (NASDAQ:KIN)

Advanced Chart

Key Stats

Today's Range
$9.24
$9.26
50-Day Range
$9.08
$9.25
52-Week Range
$3.46
$9.28
Volume
178,496 shs
Average Volume
840,890 shs
Market Capitalization
$420.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive KIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KIN Stock News Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
Kindred Hospital East Greensboro
Japan's Sony terminates $10 bln Zee India merger
European Shares Edge Higher With ECB Meeting In The Spotlight
Earnings Optimism May Contribute To Continued Strength On Wall Street
See More Headlines

KIN Stock Analysis - Frequently Asked Questions

Kindred Biosciences, Inc. (NASDAQ:KIN) released its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company earned $3.54 million during the quarter, compared to the consensus estimate of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

Last Earnings
8/05/2021
Today
7/14/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KIN
CIK
1561743
Fax
N/A
Employees
63
Year Founded
2013

Profitability

EPS (Trailing Twelve Months)
($0.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.80 million
Net Margins
-529.26%
Pretax Margin
N/A
Return on Equity
-54.19%
Return on Assets
-39.76%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
7.02
Quick Ratio
7.02

Sales & Book Value

Annual Sales
$42.16 million
Price / Sales
9.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.75 per share
Price / Book
5.29

Miscellaneous

Outstanding Shares
45,462,000
Free Float
N/A
Market Cap
$420.52 million
Optionable
Optionable
Beta
1.30

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:KIN) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners